Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sirolimus protein-bound particles

(sih-ROH-lih-mus PROH-teen-bownd PAR-tih-kulz)
A form of the drug sirolimus that is used to treat adults with malignant perivascular epithelioid cell tumor that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Sirolimus protein-bound particles may have fewer side effects and work better than other forms of sirolimus. It binds to a protein called mTOR, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Sirolimus protein-bound particles is a type of kinase inhibitor, a type of angiogenesis inhibitor, and a type of immunosuppressant. Also called Fyarro.
More Information
Search NCI's Dictionary of Cancer Terms